In remote combat environments, severe injuries often lead to sepsis, a life-threatening condition marked by an early surge of inflammation followed by dangerous immune suppression. Because current treatments struggle to restore this vital balance in delayed-care settings, injured service members are left highly vulnerable to secondary infections and poor outcomes.
To address this critical gap, Wilson Poon, Ph.D., is utilizing TRC4 Proof of Concept Research funding to develop a new class of field-deployable lipid nanoparticle (LNP) therapeutics. Engineered to target specific immune cells, these nanoparticles deliver bioactive lipids that dampen harmful inflammation and prevent immune exhaustion, providing practical, point-of-injury treatments that improve survival when conventional care is out of reach.
What Does this Funding Mean to You or Your Team?
I’m deeply grateful for the support from TRC4, which allows our team to translate fundamental advances in nanomedicine into field-ready therapies that can improve survival in the most critical moments of combat casualty care.
What Do You Hope to Accomplish Through This Project?
Our goal is to identify and validate nanoparticle systems that can precisely modulate macrophage-driven inflammation in septic conditions. We aim to create deployable immunomodulatory therapies that can stabilize patients during the critical early stages of sepsis.
What Makes this Approach Unique or Promising?
Our approach uses high-throughput, combinatorial design to systematically discover how lipid nanoparticle composition governs immune responses. Unlike traditional therapies, we target host immune dysregulation directly rather than focusing on specific pathogens. By screening hundreds of nanoparticle formulations, we can identify precise combinations that balance pro- and antiinflammatory signaling. This work integrates engineering, immunology, and data-driven design to create tunable nanoparticle platforms for immune modulation.
How Do You See this Work Contributing to National and Military Readiness?
This work supports the development of field-deployable therapies that can stabilize wounded personnel when immediate medical care is limited. Our goal is to provide therapeutic options that can be administered in austere settings to bridge the gap between injury and evacuation. By improving early-stage stabilization of septic patients, this work could enhance downstream clinical outcomes and operational effectiveness.
What Message would You Share with Others Watching this Space?
We are entering a new era where nanoparticles can be rationally engineered to precisely control immune responses, opening the door to deployable therapies for complex conditions like sepsis.